Global pharma giant Pfizer has announced that it has received an unsolicited mini-tender offer from Tutanota to buy up to 1 million shares of Pfizer stock at $32 per share in cash.
The offer is contingent on “the closing price per share of Pfizer common stock exceeding $32.00 per share on the last trading day before the offer expires,” meaning shareholders could receive a below-market price unless Tutanota waives this condition.
Tutanota “expects to extend the offer until the market price of Pfizer’s common stock exceeds the offer price,” the offer states. The shares on offer represent just 0.02% of Pfizer’s outstanding stock as of March 9, 2026.
Pfizer strongly advises caution. The company said, “Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer because the offer requires that the closing stock price for Pfizer’s common stock exceed the offer price, and it is subject to numerous additional conditions, including Tutanota obtaining financing for the offer, which Tutanota states it does not currently have.”
The offer may be extended, and Tutanota can delay payment beyond the current expiration of 5:00 p.m. US ET on Monday, April 13, 2026. “Any shareholders who tender (or have already tendered) their shares can withdraw them prior to the expiration of the offer,” Pfizer noted.
Pfizer stressed it has no affiliation with Tutanota. “Pfizer does not endorse Tutanota’s unsolicited mini-tender offer and is not affiliated or associated in any way with Tutanota, its mini-tender offer or its offer documentation.”
Mini-tender offers like Tutanota’s seek to acquire less than 5% of a company’s shares, avoiding many SEC disclosure requirements. The SEC warns that some bidders “are hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price.”
Pfizer urged shareholders to stay informed. “Pfizer urges investors to obtain current market quotations for their shares, to consult with their broker or financial advisor and to exercise caution with respect to Tutanota’s offer. Pfizer recommends that stockholders who have not responded to Tutanota’s offer take no action. Stockholders who have already tendered their shares may withdraw them at any time prior to the expiration of the offer.”
The company also advised brokers and dealers to review SEC and FINRA guidance regarding mini-tender offers and requested, “a copy of this news release be included with all distributions of materials relating to Tutanota’s mini-tender offer related to shares of Pfizer common stock.”
